

Sebastian BioPharma – Company Overview

Sebastian BioPharma is a preclinical oncology company developing a first-in-class platform based on dual-payload Antibody-Oligonucleotide Conjugates (AOCs). The company is focused on treating solid tumor patients who do not respond to current therapies, with an initial focus on colorectal cancer (CRC).

CRC is the second leading cause of cancer-related death and is rapidly increasing in incidence among patients under 50 in the U.S. Today, over 80% of patients lack effective treatment options.

The founding team, formed at the University of Miami, combines deep scientific expertise with strong execution capability. The company has secured \$7.9M in non-dilutive funding, generated multiple publications, and filed three patents. This is a capital-efficient, founder-led team with significant skin in the game, complemented by experienced advisors and consultants.

The Problem Despite major advances in immunotherapy, approximately 85% of solid tumor patients do not respond. Tumor resistance is driven by multiple interconnected biological pathways, while current therapies typically address only one. In colorectal cancer, tumors are often both "invisible" to the immune system and physically inaccessible, preventing immune cell infiltration and therapeutic effectiveness.

The Solution Sebastian BioPharma is developing a novel dual-payload AOC platform that delivers two RNA-based therapeutics simultaneously to tumor cells. This approach enables co-modulation of multiple intracellular resistance pathways in a single therapy, addressing both tumor invisibility and immune exclusion. By combining the validated modalities of Antibody-drug conjugates (ADCs) and first-generation AOCs with a dual-payload strategy, Sebastian introduces a differentiated and potentially transformative therapeutic approach.

Lead Program – SBP-001 is a dual-siRNA AOC designed for colorectal cancer. It selectively targets tumor cells and delivers two RNA payloads intracellularly to: a. increase tumor visibility to the immune system and b. enable immune cell infiltration and response.

Development Status

- Validated biological targets
- Dual-siRNA construct defined
- Demonstrated activity in vitro and in vivo
- Two candidates advancing toward drug candidate nomination
- CMC strategy and manufacturing partners identified

Pipeline The platform is scalable beyond CRC into additional solid tumors, including gastric, breast, and endometrial cancers—representing over 4 million patients annually.

Market Opportunity

- Colorectal cancer market: ~\$13B total
- ~\$6B addressable
- ~\$1B initial obtainable market

CRC represents the entry point into a broader multi-indication platform opportunity.

Business Model & Exit Sebastian BioPharma sits at the intersection of three of the most active areas in biotech: Immuno-oncology, ADCs and RNA therapeutics. Recent multi-billion-dollar transactions in the AOC and dual-payload ADC space highlight strong exit potential. The company is strategically positioned for partnership or acquisition by large pharmaceutical companies, particularly following key preclinical milestones (GLP tox and IND readiness).

The Ask Sebastian BioPharma is raising \$2.5M in a pre-seed round via SAFE (valuation cap: \$12.5M).

Proceeds will fund:

- Drug candidate nomination
- PK/PD data generation
- CMC development
- IND-enabling preparation

This round provides 12–15 months of runway and positions the company for an \$8–13M seed round to support IND filing.

Vision Sebastian BioPharma is building a scalable platform designed to make immunotherapy effective for most cancer patients. By combining first-in-class technology with a highly committed and execution-focused team, the company aims to deliver both meaningful clinical impact and significant investor value.

Contact For more information, visit [OnePage - sebastianbio.com](https://www.sebastianbio.com) sebastianbio.com or contact our CEO directly at greta.garrido@sebastianbio.com.